{"id":13699,"date":"2023-09-19T10:48:00","date_gmt":"2023-09-19T02:48:00","guid":{"rendered":"https:\/\/flcube.com\/?p=13699"},"modified":"2024-11-20T10:54:02","modified_gmt":"2024-11-20T02:54:02","slug":"suzhou-acumen-biomedical-secures-13-8-million-in-series-a-funding-round","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=13699","title":{"rendered":"Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round"},"content":{"rendered":"\n

China\u2019s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The round was led by Qiandao Investment Fund, with participation from Broad Resource Investment. The funds raised will be allocated towards the expansion of the company’s high-end product pipeline, APIs research and development, medical consumables CDMO services, and the construction of a global omni-channel network.<\/p>\n\n\n\n

Company Overview and Focus Areas<\/strong>
Founded in 2020, Acumen Bio is a leading player in the design, research and development, manufacturing, and marketing of high-end consumables and packaging materials. The company operates across various sectors, including life sciences, agriculture and animal husbandry, medical diagnosis, and drug research and development. In addition to its consumables, Acumen Bio offers comprehensive solutions and CDMO services, positioning itself as a one-stop solution provider in its field.<\/p>\n\n\n\n

Strategic Use of Funds for Growth and Expansion<\/strong>
The proceeds from the Series A+ financing round will be instrumental in fueling Acumen Bio’s growth strategy. The company plans to expand its high-end product pipeline, which is crucial for maintaining a competitive edge in the market. Investments in APIs research and development will enhance the company’s innovation capabilities, while the expansion of medical consumables CDMO services will cater to the growing demand for customized and specialized products.<\/p>\n\n\n\n

Global Omni-Channel Construction<\/strong>
A significant portion of the funds will be directed towards the construction of a global omni-channel network. This initiative will enable Acumen Bio to broaden its reach and establish a stronger presence in international markets, providing the company with access to a wider customer base and facilitating the distribution of its products and services on a global scale.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China\u2019s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2207,19,20],"class_list":["post-13699","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-acumen-biomedical-technology","tag-cro-cmo-cdmo","tag-finance"],"yoast_head":"\nSuzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The round was led by Qiandao Investment Fund, with participation from Broad Resource Investment. The funds raised will be allocated towards the expansion of the company's high-end product pipeline, APIs research and development, medical consumables CDMO services, and the construction of a global omni-channel network.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=13699\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=13699\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-19T02:48:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-20T02:54:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13699#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13699\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round\",\"datePublished\":\"2023-09-19T02:48:00+00:00\",\"dateModified\":\"2024-11-20T02:54:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13699\"},\"wordCount\":293,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Acumen Biomedical Technology\",\"CRO \\\/ CMO \\\/ CDMO\",\"Finance\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13699#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13699\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=13699\",\"name\":\"Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-09-19T02:48:00+00:00\",\"dateModified\":\"2024-11-20T02:54:02+00:00\",\"description\":\"China\u2019s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The round was led by Qiandao Investment Fund, with participation from Broad Resource Investment. The funds raised will be allocated towards the expansion of the company's high-end product pipeline, APIs research and development, medical consumables CDMO services, and the construction of a global omni-channel network.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13699#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13699\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13699#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round - Insight, China's Pharmaceutical Industry","description":"China\u2019s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The round was led by Qiandao Investment Fund, with participation from Broad Resource Investment. The funds raised will be allocated towards the expansion of the company's high-end product pipeline, APIs research and development, medical consumables CDMO services, and the construction of a global omni-channel network.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=13699","og_locale":"en_US","og_type":"article","og_title":"Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=13699","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-09-19T02:48:00+00:00","article_modified_time":"2024-11-20T02:54:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=13699#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=13699"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round","datePublished":"2023-09-19T02:48:00+00:00","dateModified":"2024-11-20T02:54:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=13699"},"wordCount":293,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Acumen Biomedical Technology","CRO \/ CMO \/ CDMO","Finance"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=13699#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=13699","url":"https:\/\/flcube.com\/?p=13699","name":"Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-09-19T02:48:00+00:00","dateModified":"2024-11-20T02:54:02+00:00","description":"China\u2019s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The round was led by Qiandao Investment Fund, with participation from Broad Resource Investment. The funds raised will be allocated towards the expansion of the company's high-end product pipeline, APIs research and development, medical consumables CDMO services, and the construction of a global omni-channel network.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=13699#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=13699"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=13699#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13699"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13699\/revisions"}],"predecessor-version":[{"id":13701,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13699\/revisions\/13701"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}